uPA AND PAI-1 In Breast Cancer: Review Of Their Clinical Utility And Current Validation In The ProspectivE NNBC-3 TRIAL

Advances in Clinical Chemistry

Volumn 45, Issue SUPPL.: COMPLETE, 2008, Pages 31-45

  Annecke, K ^a   Schmitt, M ^a   Euler, U ^a   Zerm, M ^b   Paepke, D ^a   Paepke, S ^a   von Minckwitz, G ^b   Thomssen, C ^c   Harbeck, N ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN BREAST GROUP   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

BREAST TUMOR; CLINICAL PRACTICE; CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; METABOLISM; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; VALIDATION STUDY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; URINARY PLASMINOGEN ACTIVATOR;

EID: 38649095227     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(07)00002-9     Document Type: Review

References (59)

1. Myohanen H., and Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 61 (2004) 2840-2858
2. Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol 54 (2003) 263-312
3. Longstaff C., and Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 579 (2005) 3303-3309
4. Collen D., and Lijnen H. Thrombolytic agents. Thromb Haemost 93 (2005) 627-630
5. Stassen J., Arnout J., and Deckmyn H. The hemostatic system. Curr Med Chem 11 (2004) 2245-2260
6. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L., Ploug M., et al. Plasminogen activation and cancer. Thromb Haemost 93 (2005) 676-681
7. Andreasen P., Kjoller L., Christensen L., and Duffy M. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72 (1997) 1-22
8. Mazar A., Henkin J., and Goldfarb R. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 3 (1999) 15-32
9. Schmitt M., Wilhelm O., Reuning U., Krüger A., Harbeck N., Lengyel E., et al. The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 14 (2000) 114-132
10. Laufs S., Schumacher J., and Allgayer H. Urokinase-receptor (u-PAR): An essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5 (2006) 1760-1771
11. Stefansson S., and Lawrence D. Old dogs and new tricks: Proteases, inhibitors, and cell migration. Sci STKE 2003 189 (2003) pe24
12. Medcalf R., and Stasinopoulos S. The undecided serpin. The ins and outs of plasminogen activator inhibitor type-2. FEBS J 272 (2005) 4858-4867
13. Gandolfo G., Conti L., and Vercillo M. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Anticancer Res 16 (1996) 2155-2159
14. Leissner P., Verjat T., Bachelot T., Paye M., Krause A., Puisieux A., et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 6 (2006) 216
15. Ryan B., Konecny G., Kahlert S., Wang H., Untch M., Meng G., et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17 (2006) 597-604
16. Meo S., Dittadi R., Peloso L., and Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator, and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 19 (2004) 282-288
17. Manders P., Tjan-Heijnen V., Span P., Grebenchtchikov N., Geurts-Moespot A., van Tienoven D., et al. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 101 (2004) 486-494
18. Duffy M., and Duggan C. The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37 (2004) 541-548
19. Bouchet C., Ferrero-Pous M., Hacene K., Becette V., and Spyratos F. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers 18 (2003) 207-217
20. Cufer T., Borstnar S., and Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 18 (2003) 106-115
21. Spyratos F., Bouchet C., Tozlu S., Labroquere M., Vignaud S., Becette V., et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 22 (2002) 2997-3003
22. Castello R., Estelles A., Vazquez C., Falco C., Espana F., Almenar S., et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 48 (2002) 1288-1295
23. Duffy M., O'Grady P., Devaney D., O'Siorain L., Fennelly J., and Lijnen H. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62 (1988) 531-533
24. Jänicke F., Schmitt M., Ulm K., Gossner W., and Graeff J. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2 (1989) 1049
25. Jänicke F., Schmitt M., Hafter R., Hollrieder A., Babic R., Ulm K., et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4 (1990) 69-78
26. Jänicke F., Schmitt M., and Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17 (1991) 303-312
27. Harbeck N., Kates R., Schmitt M., Gauger K., Kiechle M., Janicke F., et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5 (2004) 348-352
28. Harbeck N., Kates R., Look M., Meijer-van Gelder M., Klijn J., Krüger A., et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62 (2002) 4617-4622
29. Harbeck N., Kates R., and Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 20 (2002) 1000-1007
30. Zemzoum I., Kates R., Ross J., Dettmar P., Dutta M., Henrichs C., et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21 (2003) 1022-1028
31. Konecny G., Untch M., Arboleda J., Wilson C., Kahlert S., Boettcher B., et al. Her2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 7 (2001) 2448-2457
32. Foekens J., Peters J., Look M., Portengen H., Schmitt M., Kramer M., et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60 (2000) 636-643
33. Kim S., Shiba E., Kobayashi T., Yayoi E., Furukawa J., Takatsuka Y., et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis. Clin Cancer Res 4 (1998) 177-182
34. Meo S., Dittadi R., Peloso L., and Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 19 (2004) 282-288
35. Eppenberger U., Kueng W., Schlaeppi J., Roesel J., Benz C., Mueller H., et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16 (1998) 3129-3136
36. Hayes D., Bast R., Desch C., Fritsche H., Kemeny N., Jessup J., et al. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466
37. Jänicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93 (2001) 913-920
38. Look M., van Putten W., Duffy M., Harbeck N., Christensen I., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
39. Harbeck N., Meisner C., Prechtl A., Untch M., Selbmann H., Sweep C., et al. Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial. Breast Cancer Res Treat 69 (2001) 213
40. Jänicke F., Thomssen C., Pache L., et al. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M., Graeff H., and Jänicke F. (Eds). Prospects in Diagnosis and Treatment of Cancer (1994), Elsevier Science, Netherlands 207-218
41. Foekens J., Look M., Peters H., van Putten W., Portengen H., and Klijn J. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87 (1995) 751-756
42. Pierga J., Laine-Bidron C., Beuzeboc P., DeCremoux P., Pouillart P., and Magdelenat H. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 76 (1997) 537-540
43. Harbeck N., Kates R., Look M., Meijer-van Gelder M., Klijn J., Kruger A., et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1. Cancer Res 62 (2002) 4617-4622
44. Harbeck N., Kates R., Look M., Foekens J., and on behalf of pooled analysis study of the EORTC Receptor and Biomarker Group (RBG). Pooled analysis (n = 8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer. J Clin Oncol 23 8 (2004) 523
45. Schmitt M., Lienert S., Prechtel D., Sedlaczek E., Welk A., Reuning U., et al. The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations. J Clin Ligand Assay 25 (2002) 43-52
46. Sweep C., Geurts-Moespot J., Grebenschikov N., de Witte J., Heuvel J., Schmitt M., et al. External quality assessment of trans-European multicentre antigen determination (Enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 Inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78 (1998) 1434-1441
47. Sweep F., Fritsche H., Gion M., Klee G., Schmitt M., et al. Considerations on development, validation, application and quality control of immuno(metric) biomarker assays in clinical cancer research: An EORTC-NCI working group report. Int J Oncol 23 (2003) 1715-1726
48. Schmitt M., Harbeck N., Daidone M., Brynner N., Duffy M., Foekens J., et al. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 25 (2004) 1397-1406
49. Urban P., Vuaroqueaux V., Labuhn M., Delorenzi M., Wirapati P., Wight E., et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24 (2006) 4245-4253
50. Leissner P., Verjat T., Bachelot T., Paye M., Krause A., Puisieux A., et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 6 (2006) 216
51. Spyratos F., Bouchet C., Tozlu S., Labroquere M., Vignaud S., Becette V., et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 22 (2002) 2997-3003
52. Castello R., Estelles A., Vazquez C., Falco C., Espana F., Almenar S., et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 48 (2002) 1288-1295
53. Pakneshan P., Szyf M., and Rabbani S. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: Prognostic and therapeutic implications. Curr Cancer Drug Targets 5 (2005) 471-488
54. Pakneshan P., Tetu B., and Rabbani S. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res. 10 (2004) 3035-3041
55. Goldhirsch A., Glick J., Gelber R., Coates A., Thürlimann B., Senn H.-J., et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
56. AGO. 2006 guidelines for treatment of early and advanced breast cancer: (2006). www.ago-online.org
57. van't Veer L., Dai H., van de Vijver M., He Y., Hart A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
58. Foekens J., Atkins D., Zhang Y., Sweep F., Harbeck N., Paradiso A., et al. Multicenter validation of a gene expression based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 11 (2006) 1665-1671
59. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEJM 351 (2004) 2817-2826